Effects of an N-type calcium antagonist on angiotensin II-renin feedback

American Journal of Nephrology

Volumn 33, Issue 2, 2011, Pages 168-175

  Aritomi, Shizuka ^a   Niinuma, Kazumi ^a   Ogawa, Tetsuya ^b   Konda, Tomoyuki ^a   Nitta, Kosaku ^b  

^a AJINOMOTO CO INC   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Calcium channel blocker; Cilnidipine; Hypertension; Renin angiotensin system; Valsartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN II; CILNIDIPINE; NORADRENALIN; RENIN; VALSARTAN;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; DRUG EFFECT; HYPERTENSION; KIDNEY CORTEX; MALE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; RAT STRAIN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

AMLODIPINE; ANGIOTENSIN II; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, N-TYPE; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MODELS, BIOLOGICAL; RATS; RENIN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VALINE;

EID: 79551572457     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323969     Document Type: Article

References (41)

1. Garg R, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-1456.
2. Oparil S, Weber M: Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy. Postgrad Med 2009; 121: 25-39.
3. Hayashi K, Ozawa Y, Fujiwara K, Wakino S, Kumagai H, Saruta T: Role of actions of calcium antagonists on efferent arterioles - with special references to glomerular hypertension. Am J Nephrol 2003; 23: 229-244. (Pubitemid 36980719)
4. Takahara A: Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther 2009; 27: 124-139.
5. Takahara A, Koganei H, Takeda T, Iwata S: Antisympathetic and hemodynamic property of a dual L/N-type Ca(2+) channel blocker cilnidipine in rats. Eur J Pharmacol 2002; 434: 43-47. (Pubitemid 34033744)
6. Shiga T, Yamada Y, Matsuda N, Tanaka T, Urae A, Hashiguchi M, Hagiwara N, Kasanuki H: Influence of cilnidipine or nisoldipine on sympathetic activity in healthy male subjects. Heart Vessels 2007; 22: 404-409. (Pubitemid 350201437)
7. Nagahama S, Norimatsu T, Maki T, Yasuda M, Tanaka S: The effect of combination therapy with an L/N-Type Ca(2+) channel blocker, cilnidipine, and an angiotensin II receptor blocker on the blood pressure and heart rate in Japanese hypertensive patients: an observational study conducted in Japan. Hypertens Res 2007; 30: 815-822. (Pubitemid 47578243)
8. Varagic J, Susic D, Frohlich ED: Cilnidipine improves spontaneously hypertensive rat coronary hemodynamics without altering cardiovascular mass and collagen. J Hypertens 2002; 20: 317-322. (Pubitemid 34913798)
9. Sakata K, Yoshida H, Tamekiyo H, Obayashi K, Nawada R, Doi O, Mori N: Comparative effect of cilnidipine and quinapril on left ventricular mass in mild essential hypertension. Drugs Exp Clin Res 2003; 29: 117-123. (Pubitemid 37498413)
10. Takemori K, Ishida H, Dote K, Yamamoto K, Ito H: Prophylactic effects of an N- and Ltype Ca 2+ antagonist, cilnidipine, against cardiac hypertrophy and dysfunction in stroke-prone, spontaneously hypertensive rats. Can J Physiol Pharmacol 2005; 83: 785-790. (Pubitemid 41784017)
11. Nagai H, Minatoguchi S, Chen XH, Wang N, Arai M, Uno Y, Lu C, Misao Y, Onogi H, Kobayashi H, Takemura G, Maruyama R, Fujiwara T, Fujiwara H: Cilnidipine, an N+Ltype dihydropyridine Ca channel blocker, suppresses the occurrence of ischemia/reperfusion arrhythmia in a rabbit model of myocardial infarction. Hypertens Res 2005; 28: 361-368. (Pubitemid 40895059)
12. Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K, Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease(CARTER) Study Investigators: Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007; 72: 1543-1549. (Pubitemid 350199443)
13. Zhou X, Ono H, Ono Y, Frohlich ED: N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens 2002; 20: 993-1000. (Pubitemid 34913681)
14. Tsuchihashi T, Ueno M, Tominaga M, Kajioka T, Onaka U, Eto K, Goto K: Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine. Clin Exp Hypertens 2005; 27: 583-591. (Pubitemid 41722065)
15. Kojima S, Shida M, Yokoyama H: Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res 2004; 27: 379-385. (Pubitemid 38996928)
16. Konda T, Enomoto A, Matsushita J, Takahara A, Moriyama T: The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 2005; 101: 1-13.
17. Konda T, Enomoto A, Aritomi S, Niinuma K, Koganei H, Ogawa T, Nitta K: Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm. Am J Nephrol 2009; 30: 155-161.
18. Takahara A, Nakamura Y, Wagatsuma H, Aritomi S, Nakayama A, Satoh Y, Akie Y, Sugiyama A: Long-term blockade of L/Ntype Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart. Br J Pharmacol 2009; 158: 1366-1374.
19. Fournier A, Oprisiu-Fournier R, Serot JM, Godefroy O, Achard JM, Faure S, Mazouz H, Temmar M, Albu A, Bordet R, Hanon O, Gueyffier F, Wang J, Black S, Sato N: Prevention of dementia by antihypertensive drugs: how AT 1 -receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother 2009; 9: 1413-1431.
20. Levy BI: How to explain the differences between renin angiotensin system modulators. Am J Hypertens 2005; 18: 134S-141S. (Pubitemid 41206570)
21. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA, CHARM Investigators and Committees: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-771. (Pubitemid 37093916)
22. Forclaz A, Maillard M, Nussberger J, Brunner HR, Burnier M: Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 2003; 41: 31-36. (Pubitemid 36056788)
23. Azizi M, Ménard J, Bissery A, Guyenne TT, Bura-Rivière A, Vaidyanathan S, Camisasca RP: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT 1 receptor antagonist valsartan on the angiotensin IIrenin feedback interruption. J Am Soc Nephrol 2004; 15: 3126-3133. (Pubitemid 39578845)
24. Aritomi S, Koganei H, Wagatsuma H, Mitsui A, Ogawa T, Nitta K, Konda T: The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet. Heart Vessels 2010; 25: 549-555.
25. Nishihira T, Komatsu H, Endo Y, Shineha R, Sagawa J, Nakano T, Hoshino A, Yoshida K, Mori S: New technology for continuous intravenous infusion via the central and portal veins in the rat. Tohoku J Exp Med 1994; 173: 275-282. (Pubitemid 24324332)
26. Mochida S, Yokoyama CT, Kim DK, Itoh K, Catterall WA: Evidence for a voltage-dependent enhancement of neurotransmitter release mediated via the synaptic protein interaction site of N-type Ca 2+ channels. Proc Natl Acad Sci USA 1998; 95: 14523-14528.
27. Kopp UC, DiBona GF: Neural regulation of renin secretion. Semin Nephrol 1993; 13: 543-551. (Pubitemid 23336192)
28. Thames MC: Renin release: reflex control and adrenergic mechanisms. J Hypertens 1984; 2(Suppl 1):57-66.
29. Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ: Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003; 14: 3239-3244. (Pubitemid 37509299)
30. van den Born BJ, Koopmans RP, van Montfrans GA: The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension. Am J Hypertens 2007; 20: 900-906. (Pubitemid 47176352)
31. Sechi LA, Novello M, Colussi G, Di Fabio A, Chiuch A, Nadalini E, Casanova-Borca A, Uzzau A, Catena C: Relationship of plasma renin with a prothrombotic state in hypertension: relevance for organ damage. Am J Hypertens 2008; 21: 1347-1353.
32. Zhou MS, Schuman IH, Jaimes EA, Raij L: Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol 2008; 295:F53-F59.
33. Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G: The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag 2008; 4: 971-981.
34. McInnes GT: Renin inhibition: the holy grail of renin-angiotensin system blockade? J Hum Hypertens 2007; 21: 766-769. (Pubitemid 47454388)
35. Sharabi Y, Zimlichman R, Mansouri R, Chun J, Goldstein DS: Does acetylcholinesterase inhibition affect catecholamine secretion by adrenomedullary cells? Isr Med Assoc J 2004; 6: 396-399. (Pubitemid 38996864)
36. Bassett MH, White PC, Rainey WE: The regulation of aldosterone synthase expression. Mol Cell Endocrinol 2004; 217: 67-74. (Pubitemid 38596630)
37. Rump LC: Secondary rise of albuminuria under AT 1 -receptor blockade - what is the potential role of aldosterone escape? Nephrol Dial Transplant 2007; 22: 5-8. (Pubitemid 46050315)
38. Strauss MH, Hall AS: Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006; 114: 838-854. (Pubitemid 44274921)
39. Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T: Effect of renin-angiotensinaldosterone system triple blockade on nondiabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 2008; 31: 59-67. (Pubitemid 351325616)
40. Riche DM, Minor DS, Holdiness AS, East HE: An issue of dependence: implications from the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial. J Clin Hypertens (Greenwich) 2009; 11: 89-93.
41. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X: A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008; 51: 742-748. (Pubitemid 351301529)